To further evaluate the effects of dual HER2 blockade, we performed several experiments in 3 HER2+ breast cancer cell lines (BT474, which is HR+, SKBR3 and HCC1954, which are HR-negative) and 1 HER2-negative cell line (MCF7, which is HR+). This evidence concerns the gene ERBB2 and breast carcinoma.